公开(公告)号：US20220363671A1

公开(公告)日：2022-11-17

申请号：US17642292

申请日：2020-09-16

Applicant: NOVARTIS AG

Inventor： Jake AXFORD ,  Rohan Eric John BECKWITH ,  Simone BONAZZI ,  Nicole BUSCHMANN ,  Artiom CERNIJENKO ,  Janetta DEWHURST ,  Aleem FAZAL ,  Matthew James HESSE ,  Lauren HOLDER ,  Viktor HORNAK ,  Hidetomo IMASE ,  Rama JAIN ,  Xianming JIN ,  John Ryan KERRIGAN ,  Julie LACHAL ,  Fupeng MA ,  Hasnain Ahmed MALIK ,  James R. MANNING ,  Daniel MCKAY ,  Robert Joseph MOREAU ,  Pierre NIMSGERN ,  Gary O'BRIEN ,  Anna VULPETTI ,  Ken YAMADA ,  Junping ZHAO

IPC: C07D405/04 ,  A61K31/513 ,  C07D471/04 ,  C07D413/04 ,  C07D401/14

Abstract: Described herein are glue degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment or prevention of conditions, diseases, and disorders mediated by various target proteins.

公开(公告)号：US20210309638A1

公开(公告)日：2021-10-07

申请号：US17343016

申请日：2021-06-09

Applicant: Novartis AG

Inventor： Rohan Eric John BECKWITH ,  Simone BONAZZI ,  Artiom CERNIJENKO ,  Aleem FAZAL ,  Ritesh Bhanudasji TICHKULE ,  Michael Scott VISSER

IPC: C07D401/14 ,  C07D401/04 ,  C07D407/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D495/04 ,  C07D513/04 ,  A61P35/00

Abstract: The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, Rx, X1, n, n1, and q are as defined herein, and methods of making and using same.

公开(公告)号：US20220144807A1

公开(公告)日：2022-05-12

申请号：US17430473

申请日：2020-02-13

Applicant: Novartis AG

Inventor： Rohan Eric John BECKWITH ,  Simone BONAZZI ,  Artiom CERNIJENKO ,  Michael Scott VISSER

IPC: C07D401/14 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/501 ,  A61K31/497 ,  A61P35/00

Abstract: The present disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, R3, Rx, and n are as defined herein, and methods of making and using same.

公开(公告)号：US20220144798A1

公开(公告)日：2022-05-12

申请号：US17430478

申请日：2020-02-13

Applicant: Novartis AG

Inventor： Rohan Eric John BECKWITH ,  Simone BONAZZI ,  Artiom CERNIJENKO ,  Philip LAM ,  Noel Marie-France THOMSEN

IPC: C07D401/04 ,  C07D401/14 ,  C07D471/04

Abstract: The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, Rx, X1, X2, X3, n, n1, and q are as defined herein, and methods of making and using same.

公开(公告)号：US20190062309A1

公开(公告)日：2019-02-28

申请号：US16108713

申请日：2018-08-22

Applicant: Novartis AG

Inventor： Rohan Eric John BECKWITH ,  Simone BONAZZI ,  Artiom CERNIJENKO ,  Aleem FAZAL ,  Ritesh Bhanudasji TICHKULE ,  Michael Scott VISSER

IPC: C07D401/14 ,  A61P35/00

CPC classification number: C07D401/14 ,  A61P35/00 ,  C07D401/04 ,  C07D407/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D495/04 ,  C07D513/04

Abstract: The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, Rx, X1, n, n1, and q are as defined herein, and methods of making and using same.

公开(公告)号：US20230037639A1

公开(公告)日：2023-02-09

申请号：US17493055

申请日：2021-10-04

Applicant: Novartis AG

Inventor： Rohan Eric John BECKWITH ,  Simone BONAZZI ,  Artiom CERNIJENKO ,  Fupeng MA ,  Nathaniel F. WARE

IPC: A61K31/454 ,  A61P35/00 ,  A61K31/4545 ,  A61K31/498 ,  C07D401/04 ,  C07D401/14

Abstract: The present disclosure provides a compound of Formula (IT or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ra, Rb, Rx, R1, R2, X2, and q are as defined herein, and methods of making and using same.

公开(公告)号：US20190002393A1

公开(公告)日：2019-01-03

申请号：US16135116

申请日：2018-09-19

Applicant: Novartis AG

Inventor： Rohan Eric John BECKWITH ,  Luis BRITO ,  Brian Addison DECHRISTOPHER ,  Gabriel Grant GAMBER ,  Andrew GEALL ,  Thomas ZABAWA

IPC: C07C219/06 ,  C07D211/34 ,  A61K47/18 ,  C07D207/08 ,  C07C217/58 ,  C07C219/16 ,  C07D211/62 ,  C07C229/12 ,  A61K31/713 ,  A61K31/711 ,  A61K31/7105 ,  A61K9/51 ,  A61K9/127 ,  A61K47/22 ,  C07D295/15

Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein RA, RB, R2 and R4 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

公开(公告)号：US20180271837A1

公开(公告)日：2018-09-27

申请号：US15934176

申请日：2018-03-23

Applicant: NOVARTIS AG

Inventor： Rohan Eric John BECKWITH ,  Hua JIANG ,  Ce WANG

IPC: A61K31/422 ,  A61K31/16 ,  A61P27/16

CPC classification number: A61K31/422 ,  A61K31/16 ,  A61K31/397 ,  A61K31/4995 ,  A61K31/5377 ,  A61P27/16 ,  C07D261/08 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D487/08

Abstract: A compound of Formula (I)) or or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating hearing loss or balance disorder: wherein R1 through R3, and L are as defined herein.

公开(公告)号：US20230271940A1

公开(公告)日：2023-08-31

申请号：US18006894

申请日：2021-07-29

Applicant: Novartis AG

Inventor： Rohan Eric John BECKWITH ,  Simone BONAZZI ,  Artiom CERNIJENKO

IPC: C07D401/14 ,  C07D405/14 ,  C07D471/04

CPC classification number: C07D401/14 ,  C07D405/14 ,  C07D471/04

Abstract: The present disclosure provides a compound of Formula (I):






or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx and X1 are as defined herein, and methods of making and using same.

公开(公告)号：US20200231569A1

公开(公告)日：2020-07-23

申请号：US16835938

申请日：2020-03-31

Applicant: Novartis AG

Inventor： Rohan Eric John BECKWITH ,  Simone BONAZZI ,  Artiom CERNIJENKO ,  Aleem FAZAL ,  Ritesh Bhanudasji TICHKULE ,  Michael Scott VISSER

IPC: C07D401/14 ,  C07D401/04 ,  C07D407/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D495/04 ,  C07D513/04 ,  A61P35/00

Abstract: The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, Rx, X1, n, n1, and q are as defined herein, and methods of making and using same.